Literature DB >> 6222733

Enzymic assay of C3b receptor on intact cells and solubilized cells.

E Sim, R B Sim.   

Abstract

The C3b receptor of human erythrocytes is known to act as a cofactor for the cleavage of the complement protein C3b by the serine proteinase C3b/C4b Ina. The same cofactor activity is shown to be present on human tonsil B-lymphocytes. The cofactor activity of the C3b receptor can be assayed, on intact cells or in solubilized extracts of cells, by determining the rate of C3b cleavage in the presence of fixed concentrations of C3b and of C3b/C4b Ina. This assay method was used to compare the characteristics and relative quantities of C3b receptors on erythrocytes and lymphocytes. The cofactor activities associated with these two cell types resemble each other, but are distinct from the serum cofactor proteins, C4bp and Factor H, in antigenicity and in pH- and ionic-strength-dependence, and are distinct from Factor H in substrate specificity. Assay of cofactor activity in intact cells indicates that there are about 80-fold more receptors per cell on the lymphocyte surface than on erythrocytes. Assays with cells made permeable by detergent show that, whereas essentially all of the receptors on erythrocytes are on the cell surface, B-lymphocytes contain a large internal receptor pool, which makes up more than 80% of the total cofactor activity of the cell.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222733      PMCID: PMC1154258          DOI: 10.1042/bj2100567

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4bINA cofactor) and production of a new C3b derivative (C3b').

Authors:  S Nagasawa; R M Stroud
Journal:  Immunochemistry       Date:  1977 Nov-Dec

2.  Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads.

Authors:  P Cuatrecasas
Journal:  J Biol Chem       Date:  1970-06       Impact factor: 5.157

3.  Distribution of Fc and complement receptors in spleen sections. I. Comparison of various erythrocyte indicator systems.

Authors:  B Christensson; P Biberfeld
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

4.  Purification and structural analysis of the fourth component of human complement.

Authors:  C Bolotin; S Morris; B Tack; J Prahl
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

5.  Mouse C4 (Ss): three-step purification of its C4c fragment and production of a monospecific antiserum.

Authors:  A Ferreira; V Nussenzweig
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

6.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

7.  Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator.

Authors:  T Fujita; I Gigli; V Nussenzweig
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

8.  Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.

Authors:  A N Theofilopoulos; V A Bokisch; F J Dixon
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

9.  Complement receptor subtypes C3b and C3d in lymphatic tissue and follicular lymphoma.

Authors:  H Stein; U Siemssen; K Lennert
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  13 in total

1.  Membrane-associated complement factor H on lymphoblastoid cell lines Raji expresses a co-factor activity for the factor I-mediated cleavage of C3b.

Authors:  M J Demares
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

2.  Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway.

Authors:  Lee Aun Tan; Andrew C Yang; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2011-05-15       Impact factor: 14.870

3.  Interactions between human complement components factor H, factor I and C3b.

Authors:  C J Soames; R B Sim
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

4.  Two populations of complement factor H differ in their ability to bind to cell surfaces.

Authors:  J Ripoche; A Erdei; D Gilbert; A Al Salihi; R B Sim; M Fontaine
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

5.  Structural basis for complement factor I control and its disease-associated sequence polymorphisms.

Authors:  Pietro Roversi; Steven Johnson; Joseph J E Caesar; Florence McLean; Kirstin J Leath; Stefanos A Tsiftsoglou; B Paul Morgan; Claire L Harris; Robert B Sim; Susan M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

Review 6.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

Review 7.  The human C3b receptor.

Authors:  D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1983

8.  Large-scale isolation of complement receptor type 1 (CR1) from human erythrocytes. Proteolytic fragmentation studies.

Authors:  R B Sim
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

9.  Prediction from sequence comparisons of residues of factor H involved in the interaction with complement component C3b.

Authors:  C J Soames; A J Day; R B Sim
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

10.  Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Studies of proteolytic release of the receptor.

Authors:  J Ripoche; R B Sim
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.